Kainos Medicine, Inc.

Equities

A284620

KR7284620002

Biotechnology & Medical Research

End-of-day quote Korea S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
3,605 KRW -0.83% Intraday chart for Kainos Medicine, Inc. -0.69% -16.55%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Kainos Medicine, Inc.(KOSDAQ:A284620) dropped from S&P Global BMI Index CI
Kainos Medicine, Inc. announced that it has received KRW 2.00000052 billion in funding from SC United Co., Ltd. CI
Kainos Medicine, Inc. announced that it expects to receive KRW 2.00000052 billion in funding from SC United Co., Ltd. CI
Kainos Medicine to Raise over $37 Million via Stock Sale MT
Kainos Medicine, Inc. announced that it has received KRW 12.49997346 billion in funding from MAGNA Investment Co., Ltd., Axis Investment Co., Ltd., and other investors CI
Kainos Medicine, Inc. announced that it expects to receive KRW 12.49997346 billion in funding CI
Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine CI
Kainos Medicine, Inc.(KOSDAQ:A284620) added to S&P Global BMI Index CI
Emmaus Life Sciences Announces Collaboration with Kainos Medicine for Preclinical Development of Irak4 Inhibitor as Potential Anti-Cancer Drug CI
FAScinate Therapeutics, Inc. announced that it has received KRW 18.100000475 billion in funding from Kainos Medicine, Inc. CI
Kainos Medicine, Inc. announced that it has received KRW 20 billion in funding from SC United Co., Ltd., NH Investment & Securities Co., Ltd., KB Securities Co.,Ltd, Asset Management Arm CI
Kainos Medicine, Inc. announced that it expects to receive KRW 20 billion in funding from SC United Co., Ltd., NH Investment & Securities Co., Ltd., KB Securities Co.,Ltd, Asset Management Arm CI
Kainos Medicine, Inc. completed the acquisition of Hana Financial Eleventh Special Purpose Acquisition Company in a reverse merger transaction. CI
Kainos Medicine, Inc. agreed to acquire Hana Financial Eleventh Special Purpose Acquisition Company in a reverse merger transaction. CI
Kainos Medicine, Inc. announced that it has received KRW 3.9999933 billion in funding from NH Investment & Securities Co., Ltd., and another investor CI
Kainos Medicine, Inc. announced that it expects to receive KRW 3.9999933 billion in funding from NH Investment & Securities Co., Ltd., and another investor CI
Kainos Medicine, Inc. announced that it has received KRW 2.9999934 billion in funding from DSC Investment Inc. CI
Kainos Medicine, Inc. announced that it expects to receive KRW 2.9999934 billion in funding from DSC Investment Inc. CI
Kainos Medicine, Inc. announced that it has received KRW 1.55 billion in funding CI
Kainos Medicine, Inc. announced that it expects to receive KRW 1.55 billion in funding CI
Chart Kainos Medicine, Inc.
More charts
Kainos Medicine Inc is a Korea-based company mainly engaged in the research and development of pharmaceuticals. The Company is engaged in the research and development of degenerative brain disease treatments, antiviral drugs, anticancer drugs and other products. In addition, the Company is engaged in the research and development of Parkinson's disease drugs, AIDS drugs, blood anticancer drugs and other products.
More about the company
  1. Stock
  2. Equities
  3. Stock Kainos Medicine, Inc. - Korea S.E.
  4. News Kainos Medicine, Inc.
  5. Kainos Medicine to Raise over $37 Million via Stock Sale